Tumor BRCA testing can reveal a high tumor mutational burden related to POLE pathogenic variants

by M.-C. Villy, J. Masliah-Planchon, S. Melaabi, O. Trabelsi Grati, E. Girard, G. Bataillon, A. Vincent-Salomon, J. Le Gall, L. Golmard, D. Stoppa-Lyonnet, I. Bieche, C. Colas
Published 2021-08-01

Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers

by F. Coussy, R. El Botty, M. Lavigne, C. Gu, L. Fuhrmann, A. Briaux, L. de Koning, A. Dahmani, E. Montaudon, L. Morisset, L. Huguet, L. Sourd, P. Painsec, S. Chateau-Joubert, T. Larcher, S. Vacher, S. Melaabi, A. Vincent Salomon, E. Marangoni, I. Bieche
Published 2020-02-01